2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Abstract Number: 136

Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
Abstract Number: 137

Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents
Abstract Number: 138

Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Abstract Number: 139

Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study
Abstract Number: 140

Serum Biomarkers in a German Cohort of Patients with Systemic Juvenile Idiopathic Arthritis and Their Relationship to Response to Interleukin-1 Blockade
Abstract Number: 141

Cyclophosphamide Use in Treatment of Refractory Kawasaki Disease: A Single Center Case Series of 10 Patients and Literature Review
Abstract Number: 142

WITHDRAWN
Abstract Number: 143

Immunological Profiles Following Treatment with Rituximab in Autoimmune Disease
Abstract Number: 144

Failure of Methotrexate Monotherapy and Subsequent Response to Tumor Necrosis Factor Inhibitors in Pediatric Non-Infectious Uveitis
Abstract Number: 145

Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA
Abstract Number: 146

Immersive Virtual Reality for Management of Amplified Musculoskeletal Pain Syndrome in Adolescents: A Pilot Randomized Controlled Trial
Abstract Number: 147

Familial Clustering of Immune-mediated Diseases in Children with Abrupt-onset OCD
Abstract Number: 148

Chronic Fatigue Symptoms in Children with Abrupt Early-onset OCD And/or PANS
Abstract Number: 149

Low C4 Copy Number of Total C4 Gene, C4B Gene and C4BL Gene in Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
Abstract Number: 150

The Killer Immunoglobulin-like Receptor KIR3DL1 in Combination with HLA-Bw4 Is Associated with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].